Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes

Haemophilia

Volumn 5, Issue 3, 1999, Pages 160-168

  Andrews, J L ^a   Weaver, L ^a   Kaleko, M ^a   Connelly, S ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adenovirus; Factor VIII; Gene therapy; Hepatocytes; Primary cells

Indexed keywords

BLOOD CLOTTING FACTOR 8; COMPLEMENTARY DNA; RNA;

ADENOVIRUS; ARTICLE; CELL CULTURE; GENE CASSETTE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HEMOPHILIA A; HUMAN; HUMAN CELL; LIVER CELL; PHENOTYPE; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; CHO CELLS; CRICETINAE; DNA, COMPLEMENTARY; DOGS; FACTOR VIII; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMOPHILIA A; HUMANS; LIVER; MICE; MOLECULAR SEQUENCE DATA;

EID: 0032796661     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1999.00304.x     Document Type: Article

References (41)

1. Connelly S, Kaleko M. Haemophilia A gene therapy. Haemophilila 1998; 4: 380-8.
2. Connelly S, Kaleko M. Gene therapy for hemophilia A. Thromb Haemost 1997; 78: 31-6.
3. Smith TAG. Gene therapy for haemophilia. Exp Opin Invest Drugs 1997; 6: 1685-90.
4. Eaton DL, Wood WI, Eaton D, et al. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochem 1986; 25: 1-2.
5. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (∼95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986; 83: 5939-42.
6. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993; 81: 2925-35.
7. Gorziglia MI, Kadan MJ, Yei S, et al. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 1996; 6: 4173-8.
8. Connelly S, Andrews JL, Gallo AM, Tagliavacca L, Kaufman RJ, Kaleko M. Evaluation of an adenoviral vector encoding full-length factor VIII in hemophiliac mice. Thromb Haemost 1999; 81: 234-9.
9. Dwarki VJ, Belloni P, Nijjar T, et al. Gene therapy for hemophilia A. Production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA 1995; 92: 1023-7.
10. Lynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993; 4: 259-72.
11. Chuah MKL, Vandendriessche T, Morgan RA. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum Gene Ther 1995; 6: 1363-77.
12. Hoeben RC, van der Jagt RC, Schoute F, et al. Expression of functional factor VIII in primary human skin fibroblasts after retrovirus-mediated gene transfer. J Biol Chem 1990; 265: 7318-23.
13. Hoeben RC, Einerhand MP, Briet E, Van Ormondt H, Valerio D, Van Der Eb AJ. Toward gene therapy in haemophilia A: Retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb Haemost 1992; 67: 341-5.
14. Hoeben RC, Fallaux FJ, Van Tilburg NH, et al. Toward gene therapy for hemophilia A: Long-term persistence of factor VIII-secreting fibroblasts after transplantation into immunodeficient mice. Hum Gene Ther 1993; 4: 179-86.
15. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-42.
16. Kaufman RJ. Biological regulation of factor VIII activity. Annu Rev Med 1992; 43: 325-39.
17. Fausto N, Webber EM. Control of liver growth. Crit Rev Eukaryot Gene Expr 1993; 3: 117-35.
18. Smith TAG, Mehaffey MG, Kayda DB et al. Adeno-virus-mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402.
19. Connelly S, Smith TAG, Dhir G, et al. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 1995; 6: 185-93.
20. Connelly S, Gardner JM, Lyons RM, McClelland A, Kaleko M. Sustained expression of therapeutic levels of human factor VIII in mice. Blood 1996; 87: 4671-7.
21. Connelly S, Gardner JM, McClelland A, Kaleko M. High level tissue-specific expression of functional human FVIII in mice. Hum Gene Ther 1996; 7: 183-95.
22. Connelly S, Mount J, Mauser A, et al. Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood 1996; 88: 3846-53.
23. Connelly S, Andrews J, Gallo AM, et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 1998; 91: 3273-81.
24. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA cloned. Nature 1984; 312: 330-7.
25. Watanabe K, Saito A, Tamaoki T. Cell-specific enhancer activity in a far upstream region of the human alphafetoprotein gene. J Biol Chem 1987; 262: 4812-8.
26. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-509.
27. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
28. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding antihemophiliac factor. Nature 1984; 312: 342-6.
29. Yang L, Skotzko M, Stain S, et al. Adenoviral vector transduction of quiescent primary human hepatocytes. Int J Ped Hemotol/Oncol 1997; 4: 307-15.
30. Powell DJ, Friedman JM, Oulette AJ, Krauter KS, Darnell JEJ. Transcriptional and post-transcriptional control of specific messenger RNAs in adult and embryonic liver. J Mol Biol 1984; 179: 21-35.
31. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Sci 1980; 209: 497-9.
32. Sala-Trepat JM, Dever J, Sargent TD, Thomas K, Sell S, Bonner J. Changes in expression of albumin and alphafetoprotein genes during rat liver development and neoplasia. Biochem 1979; 18: 2167-78.
33. Abelev GI. Alpha-fetoprotein as a maker of embryo-specific differentiations in normal and tumor tissues. Transplant Rev 1974; 20: 3-37.
34. Sell S, Becker FF, Leffert HL, Watabe L. Expression of an oncodevelopmental gene product (alpha-fetoprotein) during fetal development and adult oncogenesis. Cancer Res 1976; 36: 4239-49.
35. Spergel JM, Chen-Kiang S. Interleukin 6 enhances a cellular activity that functionally substitutes for E1A protein in transactivation. Proc Natl Acad Sci USA 1991; 88: 6472-6.
36. Ledley FD. Hepatocellular transplantation in acute hepatic function and targeting genetic markers to hepatic cells. Hum Gene Ther 1991; 2: 331-58.
37. Meulien P, Faure T, Mischler F, et al. A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII. Protein Eng 1988; 2: 301-6.
38. Dorner AJ, Bole DG, Kaufman RJ. The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol 1987; 105: 2665-74.
39. Rosenberg JB, Foster PA, Kaufman RJ, et al. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest 1998; 101: 613-24.
40. Flynn GC, Chappell TG, Rothman JE. Peptide binding and release by proteins implicated as catalysts of protein assembly. Sci 1989; 245: 385-90.
41. Castell JV, Gomez-Lechon MJ, Ponsoda X, Bort R. The use of cultured hepatocytes to investigate the mechanisms of drug hepatotoxicity. Cell Biol Toxicol 1997; 13: 331-8